Company: RCUS
Filing Date: 2025-10-28
Form Type: 10-Q
Source: 0001724521-25-000116
Chunk: 216

Company: Arcus Biosciences, Inc.
Filing Date: 2025-10-28
Form: 10-Q
Item: Part I, Item 1
Chunk 216
---
 securitiesBetween one and three years10 14 Total cash, cash equivalents and marketable securities $841 $992 Realized gains or losses recognized on the sale of available-for-sale marketable securities were not material for the three and nine months ended September 30, 2025 and 2024 and are included in Interest and other income, net, in the Condensed Consolidated Statements of Operations. The cost of a security sold is determined using the specific-identification method.

15

We limit the credit risk associated with our investments by placing them with banks and institutions we believe are highly credit worthy and investing in highly rated investments. We held a total of 21 and 54 positions in securities which were in unrealized loss positions as of September 30, 2025 and December 31, 2024, respectively, which were immaterial individually and in aggregate. We do not intend to sell our securities with unrealized loss positions and have concluded we will not be required to sell the securities before recovery of the amortized cost for the investment at maturity. No credit related losses have been recognized for any of the periods presented.The following table provides a reconciliation of cash, cash equivalents, and restricted cash within the Condensed Consolidated Balance Sheets to the total shown in the Condensed Consolidated Statements of Cash Flows (in millions):As of September 30,20252024Cash and cash equivalents$238 $201 Restricted cash (included in Other noncurrent assets)3 3 Total cash, cash equivalents and restricted cash$241 $204 Restricted cash at September 30, 2025 and 2024 represents cash balances held as security in connection with our facility lease agreements.

Note 10. Condensed consolidated balance sheet components

Prepaid Expenses and Other Current AssetsPrepaid expenses and other current assets consisted of the following (in millions):September 30, 2025December 31, 2024Prepaid expenses and other assets$12 $13 Accrued interest receivable3 5 Total prepaid expenses and other current assets$15 $18 Other Current LiabilitiesOther current liabilities consisted of the following (in millions):September 30, 2025December 31, 2024Accrued research and development$84 $65 Accrued personnel expenses28 31 Current portion of lease liabilities13 12 Other16 15 Total other current liabilities$141 $123 

Note 11. Long-term debt